Trial Profile
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Degarelix (Primary) ; Leuprorelin (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PRESTO
- 01 Jul 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 01 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 06 Jun 2023 Results assessing Depth of PSA nadir and subsequent PSA progression-free survival in patients with high-risk biochemically relapsed prostate cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology